Skip to main content
Advertisement
Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis

May 3, 2024

Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis

Lyndon P. James and team investigate the health impact and cost-effectiveness of a 6-month BPaLM regimen versus standard of care for the treatment of rifampicin-resistant tuberculosis in Moldova.

Image credit: National Institute of Allergy and Infectious Diseases, Unsplash

05/10/2024

Research Article

Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial

De-Shen Wang and colleagues evaluate the efficacy and safety of cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as a conversion regimen in patients with colorectal cancer and initially unresectable colorectal liver metastases.

Image credit: National Cancer Institute, Unsplash

Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial

Get new content from PLOS Medicine in your inbox

Thank you! You have successfully subscribed to the PLOS Medicine newsletter.

Sorry, an error occurred while sending your subscription. Please try again later.

Try again
PLOS Medicine | ISSN: 1549-1676 (online)